Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 6
2005 3
2006 5
2007 1
2008 5
2009 5
2010 6
2011 8
2012 3
2013 3
2014 11
2015 10
2016 7
2017 4
2018 5
2019 6
2020 13
2021 10
2022 10
2023 5

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Limitations of non-invasive tests for assessment of liver fibrosis.
Patel K, Sebastiani G. Patel K, et al. JHEP Rep. 2020 Jan 20;2(2):100067. doi: 10.1016/j.jhepr.2020.100067. eCollection 2020 Apr. JHEP Rep. 2020. PMID: 32118201 Free PMC article. Review.
The diagnostic assessment of liver injury is an important step in the management of patients with chronic liver disease (CLD). Although liver biopsy is the reference standard for the assessment of necroinflammation and fibrosis, the inherent limitations of an …
The diagnostic assessment of liver injury is an important step in the management of patients with chronic liver disease (CLD). …
Reply.
Galvin Z, Patel K, Bhat M. Galvin Z, et al. Among authors: patel k. Liver Transpl. 2019 Jun;25(6):969-970. doi: 10.1002/lt.25465. Epub 2019 Apr 29. Liver Transpl. 2019. PMID: 30947397 No abstract available.
Reply.
Choi HSJ, Brouwer WP, Hansen BE, Janssen HLA, Patel K. Choi HSJ, et al. Among authors: patel k. Hepatology. 2020 Feb;71(2):769. doi: 10.1002/hep.30980. Epub 2020 Jan 28. Hepatology. 2020. PMID: 31593309 No abstract available.
Reply.
Patel K, Chung C, Myers RP. Patel K, et al. Hepatology. 2020 Dec;72(6):2241-2242. doi: 10.1002/hep.31402. Epub 2020 Nov 20. Hepatology. 2020. PMID: 32490551 No abstract available.
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, Bhandari BR, Gunn N, Caldwell SH, Goodman Z, Wapinski I, Resnick M, Beck AH, Ding D, Jia C, Chuang JC, Huss RS, Chung C, Subramanian GM, Myers RP, Patel K, Borg BB, Ghalib R, Kabler H, Poulos J, Younes Z, Elkhashab M, Hassanein T, Iyer R, Ruane P, Shiffman ML, Strasser S, Wong VW, Alkhouri N; ATLAS Investigators. Loomba R, et al. Among authors: patel k. Hepatology. 2021 Feb;73(2):625-643. doi: 10.1002/hep.31622. Hepatology. 2021. PMID: 33169409 Clinical Trial.
BACKGROUND AND AIMS: Advanced fibrosis attributable to NASH is a leading cause of end-stage liver disease. APPROACH AND RESULTS: In this phase 2b trial, 392 patients with bridging fibrosis or compensated cirrhosis (F3-F4) were randomized to receive placebo, selonsertib 18 …
BACKGROUND AND AIMS: Advanced fibrosis attributable to NASH is a leading cause of end-stage liver disease. APPROACH AND RESULTS: In t …
NASH in HIV.
Cervo A, Shengir M, Patel K, Sebastiani G. Cervo A, et al. Among authors: patel k. Curr HIV/AIDS Rep. 2020 Dec;17(6):601-614. doi: 10.1007/s11904-020-00531-0. Curr HIV/AIDS Rep. 2020. PMID: 32984925 Review.
Nonalcoholic fatty liver disease (NAFLD) seems a frequent comorbidity in aging PWH nowadays. NAFLD results from a fat deposition into the liver parenchyma that may evolve to nonalcoholic steatohepatitis (NASH), a state of hepatocellular inflammation and injury in re …
Nonalcoholic fatty liver disease (NAFLD) seems a frequent comorbidity in aging PWH nowadays. NAFLD results from a fat deposition into …
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, Janssen HLA, de Knegt RJ, Sonneveld MJ. van Kleef LA, et al. Among authors: patel k. JHEP Rep. 2021 Aug 8;3(5):100350. doi: 10.1016/j.jhepr.2021.100350. eCollection 2021 Oct. JHEP Rep. 2021. PMID: 34557660 Free PMC article.
LAY SUMMARY: Recently, metabolic dysfunction-associated fatty liver disease (MAFLD) has been defined as fatty liver disease with signs of metabolic dysfunction. Among patients with chronic hepatitis B, MAFLD was associated with liver-related events and death. …
LAY SUMMARY: Recently, metabolic dysfunction-associated fatty liver disease (MAFLD) has been defined as fatty liver disease wi …
Fibroscan.
Patel K, Wilder J. Patel K, et al. Clin Liver Dis (Hoboken). 2014 Dec 9;4(5):97-101. doi: 10.1002/cld.407. eCollection 2014 Nov. Clin Liver Dis (Hoboken). 2014. PMID: 30992931 Free PMC article. Review. No abstract available.
Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort.
Sharma D, Gotlieb N, Farkouh ME, Patel K, Xu W, Bhat M. Sharma D, et al. Among authors: patel k. J Am Heart Assoc. 2022 Jan 4;11(1):e022576. doi: 10.1161/JAHA.121.022576. Epub 2021 Dec 20. J Am Heart Assoc. 2022. PMID: 34927450 Free PMC article.
Background Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide. ...
Background Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide. ...
Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.
Alhinai A, Patel K, Fonseca VA, Sebastiani G. Alhinai A, et al. Among authors: patel k. J Diabetes Complications. 2021 Sep;35(9):107978. doi: 10.1016/j.jdiacomp.2021.107978. Epub 2021 Jun 19. J Diabetes Complications. 2021. PMID: 34183247 Review.
Due to a common underlying pathogenic mechanism, namely insulin resistance, T2D represents the main risk factor for nonalcoholic fatty liver disease (NAFLD), characterized by a buildup of fat in the liver. ...Liver fibrosis progression and development of cirr …
Due to a common underlying pathogenic mechanism, namely insulin resistance, T2D represents the main risk factor for nonalcoholic fatty li …
118 results